These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38374188)

  • 1. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
    Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
    Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells.
    Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
    Pathol Res Pract; 2023 Apr; 244():154418. PubMed ID: 36989844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine Tumors.
    Kim J; Yang DH; Jung H; Cho H; Jang HJ; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
    Arch Pathol Lab Med; 2023 Jul; 147(7):797-807. PubMed ID: 36191342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of protein expression of cyclooxygenase-2 and somatostatin receptors in gastroenteropancreatic neuroendocrine tumors.
    Kim HS; Lee HS; Kim WH
    Cancer Res Treat; 2011 Sep; 43(3):181-8. PubMed ID: 22022296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
    Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
    Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors.
    Watanabe H; Fujishima F; Komoto I; Imamura M; Hijioka S; Hara K; Yatabe Y; Kudo A; Masui T; Tsuchikawa T; Sakamoto K; Shiga H; Nakamura T; Nakaya N; Motoi F; Unno M; Sasano H
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors.
    Fotouhi O; Zedenius J; Höög A; Juhlin CC
    Neuro Endocrinol Lett; 2018 Oct; 39(4):305-309. PubMed ID: 30531706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
    van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
    Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
    Sherman SK; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    Surgery; 2013 Dec; 154(6):1206-13; discussion 1214. PubMed ID: 24238043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
    Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A Expression in Rectal Neuroendocrine Tumors Is Associated With More Aggressive Clinical Behavior and a Poorer Prognosis.
    Kim J; Kim JY; Oh EH; Yoo C; Park IJ; Yang DH; Ryoo BY; Ryu JS; Hong SM
    Am J Surg Pathol; 2020 Nov; 44(11):1496-1505. PubMed ID: 32735108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
    Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.